Hindson Benjamin J.'s Form 4 filing
10x Genomics, Inc. (TXG) · filed Aug 3, 2023
- Accession no.
- 0001610717-23-000222
- Filed
- Aug 3, 2023
- Trade date
- Aug 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $433.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hindson Benjamin J.CIK 0001786391 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | Class A Common Stock | MOption exerciseAcquired | +6,970 | $11.48 | +$80,015.6 | 291,206 | Direct | |
| Aug 1, 2023 | Class A Common Stock | SSaleDisposed | −1,727 | $61.77F2 | −$106,676.79 | 289,479 | Direct | |
| Aug 1, 2023 | Class A Common Stock | SSaleDisposed | −5,243 | $62.36F3 | −$326,953.48 | 284,236 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | Class A Common Stock | MOption exerciseDisposed | −6,970 | $0.00 | $0 | 23,312 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $61.12 to $62.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $62.12 to $62.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Scientific Officer